血清Gal-1、VEGF预测重度子痫前期患者胎盘早剥的价值及危险因素分析
Predictive value of serum Gal-1 and VEGF for placental abruption in severe preeclampsia and identification of associated risk factors
目的 探讨血清半乳糖凝集素-1(Gal-1)、血管内皮生长因子(VEGF)检测在评估重度子痫前期(PE)患者胎盘早剥(PA)中的临床价值,并分析其相关危险因素。 方法 回顾性分析2023年1月—2025年1月西北妇女儿童医院收治的273例重度PE产妇的临床资料,根据产妇是否发生PA分为早剥组(46例)与无早剥组(227例)。收集上述研究对象的一般临床资料。检测并比较各组产妇血清相关指标水平。采用多因素一般Logistic回归模型分析重度PE患者发生PA的危险因素。采用受试者工作特征(ROC)曲线分析其对重度PE产妇发生PA的预测价值。 结果 早剥组间接胆红素、肌酐、尿素氮均高于无早剥组(P <0.05),纤维蛋白原低于无早剥组(P <0.05);早剥组Gal-1、白细胞介素-12(IL-12)、胎盘生长因子(PLGF)、Fibulin-5、血管生成素-2(Ang-2)均低于无早剥组(P <0.05),VEGF高于无早剥组(P <0.05)。ROC曲线结果显示,Gal-1、VEGF、IL-12、PLGF、Fibulin-5、Ang-2联合预测重度PE产妇发生PA的敏感性为97.8%(95% CI:0.885,0.999),特异性为99.1%(95% CI:0.969,0.999),曲线下面积为0.977(95% CI:0.942,1.000)。多因素一般Logisitc回归分析结果显示:高VEGF水平[O^R =3.025(95% CI:1.216,7.527)]为重度PE患者发生PA的危险因素(P <0.05);高Gal-1水平[O^R =0.781(95% CI:0.679,0.899)]、高IL-12水平[O^R =0.824(95% CI:0.704,0.963)]、高PLGF水平[O^R =0.953(95% CI:0.912,0.996)]、高Fibulin-5水平[O^R =0.816(95% CI:0.742,0.897)]、高Ang-2水平[O^R =0.570(95% CI:0.343,0.948)]均为重度PE患者发生PA的保护因素(P <0.05)。 结论 重度PE合并PA患者血清Gal-1、IL-12、PLGF、Fibulin-5、Ang-2水平显著降低,VEGF水平升高。联合检测上述指标可显著提高PA的预测效能,且高VEGF水平为独立危险因素,而高Gal-1、IL-12、PLGF、Fibulin-5、Ang-2水平为保护因素。
Objective To explore the clinical value of serum galectin-1 (Gal-1) and vascular endothelial growth factor (VEGF) in assessing placental abruption (PA) in patients with severe preeclampsia (PE), and to analyze the associated risk factors. Methods A retrospective analysis was conducted on 231 patients with severe PE admitted to Northwest Women and Children's Hospital between January 2023 and January 2025. Based on the presence or absence of PA, patients were divided into the abruption group (n = 46) and the non-abruption group (n = 185). General clinical data and serum biomarker levels were collected and compared between the two groups. Multivariable logistic regression was used to identify risk factors for PA in severe PE patients. Receiver operating characteristic (ROC) curves were used to analyze the predictive value of each indicator for PA. Results The abruption group showed significantly higher levels of indirect bilirubin, creatinine, and blood urea nitrogen compared to the non-abruption group (P < 0.05), while the fibrinogen level was significantly lower in the abruption group (P < 0.05). Furthermore, the abruption group had significantly lower levels of Gal-1, IL-12, PLGF, Fibulin-5, and Ang-2 (P < 0.05), but a significantly higher level of VEGF (P < 0.05). ROC curve analysis demonstrated that the combined biomarkers for predicting PA in severe PE patients yielded a sensitivity of 97.8% (95% CI: 0.885, 0.999), a specificity of 99.1% (95% CI: 0.969, 0.999), and an area under the curve of 0.977 (95% CI: 0.942, 1.000). Multivariable logistic regression analysis revealed that a high VEGF level was an independent risk factor for PA in severe PE patients [O^R = 3.025 (95% CI: 1.216, 7.527), P < 0.05]. Conversely, high levels of Gal-1 [O^R = 0.781 (95% CI: 0.679, 0.899) ], IL-12 [O^R = 0.824 (95% CI: 0.704, 0.963) ], PLGF [O^R = 0.953 (95% CI: 0.912, 0.996) ], Fibulin-5 [O^R = 0.816 (95% CI: 0.742, 0.897) ], and Ang-2 [O^R = 0.570 (95% CI: 0.343, 0.948) ] were identified as independent protective factors (P < 0.05). Conclusion In patients with severe PE complicated by PA, serum levels of Gal-1, IL-12, PLGF, Fibulin-5, and Ang-2 are significantly decreased, while VEGF levels are elevated. The combined detection of Gal-1, VEGF, and other related biomarkers significantly enhances the predictive efficacy for PA. Elevated VEGF levels represent an independent risk factor, whereas higher levels of Gal-1, IL-12, and other related biomarkers act as protective factors.
| [1] |
顾玉婵, 贾丽华. 血清STOX1 sFlt-1 TM对早发型重度子痫前期并发胎盘早剥的预测价值[J]. 安徽医学, 2024, 45(3): 317-321. |
| [2] |
李兰花, 杜秀萍, 杨姗姗, 血清Fibulin-3与Ang2水平预测重度子痫前期患者胎盘早剥价值[J]. 中国计划生育学杂志, 2023, 31(2): 438-442. |
| [3] |
仲蓉蓉, 韩艳. 改良早期预警评分联合快速反应系统在重度子痫前期患者中的应用效果[J]. 中国医药导报, 2024, 21(14): 172-175. |
| [4] |
许文娟, 鲁小龙, 张雷, 重度子痫前期孕妇外周血T淋巴细胞亚群和NK细胞变化及其对母婴结局影响[J]. 中国计划生育学杂志, 2023, 31(4): 822-826. |
| [5] |
郭妮, 刘春利, 刁艳君, 子痫前期患者血清Fibulin-3、PAPP-A及PLGF的表达变化及其与胎盘早剥的相关性及预测价值分析[J]. 临床和实验医学杂志, 2023, 22(22): 2409-2412. |
| [6] |
李文婷, 赵荣. 前列环素、神经肽Y与子痫前期关系及对胎盘早剥的预测价值研究[J]. 陕西医学杂志, 2023, 52(2): 145-148. |
| [7] |
WILLIAMS S, TRAN C, FORSETER S. Coinciding placental abruption and pulmonary edema in a patient with preeclampsia[J]. Cureus, 2024, 16(8): e66065. |
| [8] |
中华医学会. 临床诊疗指南·妇产科学分册[M]. 北京: 人民卫生出版社, 2011: 122. |
| [9] |
KUMARI A, PRASAD I, SAHAY N, et al. A rare case with double trouble: Peripartum cardiomyopathy and preeclampsia together with placental abruption resulting in both cardiac and kidney failure[J]. J Family Med Prim Care, 2024, 13(7): 2789-2791. |
| [10] |
黄雪霞, 顾惠凤, 沈萍华, 因果分析护理对重度子痫前期患者妊娠结局及产后效能感的影响[J]. 中华全科医学, 2025, 23(3): 530-533. |
| [11] |
ABE M, ARIMA H, YOSHIDA Y, et al. Optimal blood pressure target to prevent severe hypertension in pregnancy: a systematic review and meta-analysis[J]. Hypertens Res, 2022, 45(5): 887-899. |
| [12] |
李敏, 郑淑敏, 张红霞, 孕期子宫动脉超声参数、血清PIGF水平与子痫前期风险的相关性研究[J]. 中华全科医学, 2025, 23(2): 257-260. |
| [13] |
霍晓燕, 薛洁, 张利玲, 子痫前期孕妇血清sFlt-1、FGF-19水平与妊娠结局的关系研究[J]. 中国现代医学杂志, 2025, 35(13): 6-11. |
| [14] |
COTTRELL J, AL SANANI A, OGU I, et al. Triple positive antiphospholipid antibody syndrome in pregnancy with high frequency plasma exchange: a case report[J]. Transfus Med Hemother, 2023, 50(2): 154-158. |
| [15] |
顾梦薇, 丁丽娟, 陈晨. 子痫前期孕妇胎盘组织自噬相关蛋白的表达及其临床意义[J]. 中国现代医学杂志, 2024, 34(18): 77-82. |
| [16] |
张佳佳, 单习瑞. 低分子肝素联合拉贝洛尔治疗早发型重度子痫前期的效果及对妊娠结局的影响评价[J]. 世界中医药, 2024, 19(17): 后插4. |
| [17] |
林雪燕, 杨孜, 张雪芹, 二线城市三级孕产妇转诊中心重度子痫前期临床特点分析[J]. 中华妇产科杂志, 2023, 58(6): 423-429. |
| [18] |
汪文昕, 汪若兰, 方媛媛, 妊娠期高血压疾病单胎妊娠并发胎盘早剥的风险预测[J]. 中华全科医学, 2024, 22(8): 1367-1370. |
| [19] |
赵文血, 王玉贤. 尿酸与子痫前期分娩结局的相关性及对重度子痫前期的辅助诊断价值[J]. 中国妇幼保健, 2023, 38(5): 797-800. |
| [20] |
张丽萍, 李霞, 谢艳. sPE患者血清miR-199a-5p、miR-142-3p表达变化及与产妇血管内皮损伤、围产儿结局的关系[J]. 山东医药, 2023, 63(36): 15-19. |
| [21] |
SANUSI A A, SINKEY R G, TITA A T N. Clinical trials that have changed obstetric practice: the chronic hypertension and pregnancy (CHAP) trial[J]. Clin Obstet Gynecol, 2024, 67(2): 411-417. |
| [22] |
KEEPANASSERIL A, BHARATHI V, BOBBY Z, et al. Serum biomarkers of maternal morbidity and adverse outcome in severe pre-eclampsia[J]. Eur J Obstet Gynecol Reprod Biol, 2022, 270: 190-194. |
| [23] |
LIU S H, ZHOU L L, SONG B, et al. Uterine torsion complicated by severe placental abruption in the second trimester: a case report and literature review[J]. BMC Pregnancy Childbirth, 2023, 23(1): 51. |
| [24] |
GOLDBART A, PARIENTE G, SHEINER E, et al. Identifying risk factors for placental abruption in subsequent pregnancy without a history of placental abruption[J]. Int J Gynaecol Obstet, 2023, 161(2): 406-411. |
| [25] |
ZENG X Y, YANG Y. Molecular mechanisms underlying vascular remodeling in hypertension[J]. Rev Cardiovasc Med, 2024, 25(2): 72. |
陕西省重点研发计划一般项目(2022SF-055)
/
| 〈 |
|
〉 |